Emm secures £6.8m seed to measure menstrual flow with connected cup
This article covers Emm, a UK healthtech startup, which has raised £6.8m in an oversubscribed seed round to commercialise a connected menstrual cup and companion app. The funding is intended to bring the product to UK consumers in early 2026 and to support further clinical development of an objective menstrual measurement tool to provide longitudinal data for users and clinicians.
Emm, a healthtech startup based in the UK, has raised £6.8 million in an oversubscribed seed round to commercialise a connected menstrual cup and companion app. The funding aims to bring the product to UK consumers in early 2026 and to support further clinical development of an objective menstrual measurement tool — a gap many clinicians and patients say has left menstrual health under‑measured and under‑researched.
Why it matters
Menstrual and reproductive health affect roughly half the population, yet reliable, longitudinal measurement of menstrual symptoms and flow has been limited. Emm says its product will provide objective measures of flow volume, cycle regularity and duration, offering baseline data that could change how people and clinicians diagnose and manage conditions that cause severe menstrual symptoms. The company cites figures that one in three women will experience severe menstrual or reproductive health symptoms in their lifetime to underline the unmet need.
Inside the product
Emm has spent five years iterating a non‑intrusive cup that integrates medical‑grade silicone with ultra‑thin sensing hardware. The cup pairs with a connected app that the company says will build an individual baseline over approximately three cycles, automatically collating metrics such as flow volume, frequency and regularity. Emm positions the device and app as a platform intended both for personal insights and for clinical conversations, and says it has prioritised user privacy.
The product is due to launch in the UK in early 2026, with other markets to follow. Emm also reports it has received non‑dilutive grants supporting innovation in women’s health technology.
Who are the investors?
The £6.8 million seed round was led by Lunar Ventures. Additional participants include the Labcorp Venture Fund, Tiny VC, BlueLion Global, Alumni Ventures (an investor in Oura and Levels), and a syndicate of angel investors including Amar Shah, Vivek Garipalli and Harpreet Rai.
The company says the round was oversubscribed. Alumni Ventures’ prior investments in wearable and metabolic monitoring businesses were highlighted as context for the fund’s participation.
In the announcement, Mick Halsband, Partner at Lunar Ventures, commented:
We’re proud to back Jenny and the Emm team as they build the foundational technology to transform women’s health and drive measurable impact in chronic diseases. At Lunar, we invest in founders tackling complex engineering challenges across data, materials, and biological systems, and Emm exemplifies this with its world-class hardware and high-fidelity data. Their world-first platform has the potential to redefine standards of care and data quality in menstrual health and beyond.
In the announcement, Megann Vaughn Watters, VP of New Ventures & Strategic Alliances at Labcorp, said:
We see tremendous value in innovations that give people more control over their own health with actionable data and insights. We are excited to support Emm as they strive to bridge the gap in access to reliable menstrual health data and change the way reproductive health conditions are researched, diagnosed and discussed by both consumers and clinicians.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Jenny Button founded Emm in 2020 with the stated aim of improving outcomes in women’s health. The company’s board is chaired by Grace E. Colón, PhD, who has nearly 30 years’ experience across biopharma, genomics and healthcare and serves on multiple corporate and nonprofit boards including Voyager Therapeutics, MIT and BIO.
In the announcement, Jenny Button, founder and CEO of Emm, said:
Menstruation is known as the fifth vital sign, but has historically been overlooked by the wearable sector, leaving millions without the data they need to understand and advocate for their own bodies. We envision a future where menstrual health is measured and understood as comprehensively as cardiovascular or metabolic health, giving people access to objective, actionable insights to better manage their health and wellbeing.
In the announcement, Grace E. Colón, PhD, Board Chair, said:
Emm’s technology has the potential to serve as both a biological sample and data insights platform, unlocking new knowledge and opportunities for researchers and biotech focused on women’s health and beyond. I am thrilled to partner with Jenny and her team to provide tools that are desperately needed and catalyze what we anticipate will be major advances for patients.
The bigger picture
Emm’s product sits at the intersection of wearables, diagnostics and reproductive health research. If it delivers reliable flow metrics at scale, it could provide a dataset for clinical research and improve diagnostic conversations for conditions such as endometriosis and menorrhagia, which are often diagnosed late. The company will still need to navigate clinical validation, regulatory pathways and adoption by clinicians if it is to influence standards of care.
The deal also reflects continued investor appetite in UK healthtech startups that combine hardware, sensors and longitudinal health data. Emm’s board links to institutions such as MIT and the University of Cambridge, and partnerships with clinical or research organisations will be important as the business moves from device prototype to a clinically useful tool.
This funding round and planned UK launch add to the growing number of European ventures aiming to modernise reproductive health monitoring, and will be one to watch for its potential to shift how menstrual health is measured and treated across clinical and consumer settings.
They've invested in Emm
Get to know these healthtech investors
Click here for a full list of 7,233+ startup investors in the UK